These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
417 related articles for article (PubMed ID: 11916246)
21. IL-2 inhibits proliferation of K562 cells and reduces accumulation of bcr/abl mRNA and oncoprotein. Dilloo D; Hanenberg H; Lion T; Burdach S Leukemia; 1995 Mar; 9(3):419-24. PubMed ID: 7885040 [TBL] [Abstract][Full Text] [Related]
22. Cleavage of BCR/ABL mRNA by synthetic ribozymes--effects on the proliferation rate of K562 cells. Lange W Klin Padiatr; 1995; 207(4):222-4. PubMed ID: 7564157 [TBL] [Abstract][Full Text] [Related]
23. Nuclear topography and expression of the BCR/ABL fusion gene and its protein level influenced by cell differentiation and RNA interference. Bártová E; Harnicarová A; Pacherník J; Kozubek S Leuk Res; 2005 Aug; 29(8):901-13. PubMed ID: 15978941 [TBL] [Abstract][Full Text] [Related]
24. [Study on the in vitro cleavage abilities of ribozymes specific to different sites of bcr-abl fusion gene and their induction of apoptosis in K562 cells]. Feng Q; Sun B; Zhao Y Zhonghua Yi Xue Za Zhi; 2000 Feb; 80(2):127-30. PubMed ID: 11798747 [TBL] [Abstract][Full Text] [Related]
25. Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells. Nimmanapalli R; Bali P; O'Bryan E; Fuino L; Guo F; Wu J; Houghton P; Bhalla K Cancer Res; 2003 Nov; 63(22):7950-8. PubMed ID: 14633726 [TBL] [Abstract][Full Text] [Related]
26. Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation. Cilloni D; Messa F; Gottardi E; Fava M; Arruga F; Defilippi I; Carturan S; Messa E; Morotti A; Giugliano E; Rege-Cambrin G; Alberti D; Baccarani M; Saglio G Cancer; 2004 Sep; 101(5):979-88. PubMed ID: 15329907 [TBL] [Abstract][Full Text] [Related]
27. [Monitoring bcr-abl mRNA levels by real-time quantitative RT-PCR in chronic myeloid leukemia patients after hematopoietic stem cell transplantation]. Qin YZ; Li JL; Zhu HH; Ruan GR; Li LD; Zhang Y; Xu LP; Liu DH; Liu YR; Huang XJ; Chen SS; Lu DP Zhonghua Xue Ye Xue Za Zhi; 2006 Aug; 27(8):511-4. PubMed ID: 17172121 [TBL] [Abstract][Full Text] [Related]
28. Ex vivo effects associated with the expression of a bcr-abl-specific ribozyme in a CML cell line. Wright LA; Milliken S; Biggs JC; Kearney P Antisense Nucleic Acid Drug Dev; 1998 Feb; 8(1):15-23. PubMed ID: 9512092 [TBL] [Abstract][Full Text] [Related]
29. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. Wetzler M; Talpaz M; Van Etten RA; Hirsh-Ginsberg C; Beran M; Kurzrock R J Clin Invest; 1993 Oct; 92(4):1925-39. PubMed ID: 8408645 [TBL] [Abstract][Full Text] [Related]
30. Stable RNA interference (RNAi) as an option for anti-bcr-abl therapy. Scherr M; Battmer K; Schultheis B; Ganser A; Eder M Gene Ther; 2005 Jan; 12(1):12-21. PubMed ID: 15602589 [TBL] [Abstract][Full Text] [Related]
31. Transcriptional activation of human LIM-HOX gene hLH-2 in chronic myelogenous leukemia is due to a cis-acting effect of Bcr-Abl. Wu HK; Minden MD Biochem Biophys Res Commun; 1997 May; 234(3):742-7. PubMed ID: 9175786 [TBL] [Abstract][Full Text] [Related]
33. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction]. Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019 [TBL] [Abstract][Full Text] [Related]
34. Impact of BCR/ABL gene expression on the proliferative rate of different subpopulations of haematopoietic cells in chronic myeloid leukaemia. Primo D; Flores J; Quijano S; Sanchez ML; Sarasquete ME; del Pino-Montes J; Gaarder PI; Gonzalez M; Orfao A Br J Haematol; 2006 Oct; 135(1):43-51. PubMed ID: 16939497 [TBL] [Abstract][Full Text] [Related]
35. In vitro and in vivo effects of synthetic ribozymes targeted against BCR/ABL mRNA. Lange W; Cantin EM; Finke J; Dölken G Leukemia; 1993 Nov; 7(11):1786-94. PubMed ID: 8231247 [TBL] [Abstract][Full Text] [Related]
36. Multi-unit ribozyme-mediated cleavage of bcr-abl mRNA in myeloid leukemias. Leopold LH; Shore SK; Newkirk TA; Reddy RM; Reddy EP Blood; 1995 Apr; 85(8):2162-70. PubMed ID: 7718886 [TBL] [Abstract][Full Text] [Related]